| Pharmacy (English) | |||||
| Bachelor | TR-NQF-HE: Level 6 | QF-EHEA: First Cycle | EQF-LLL: Level 6 | ||
| Course Code: | UNI320 | ||||
| Course Name: | Health & Microbiome | ||||
| Semester: | Spring | ||||
| Course Credits: |
|
||||
| Language of instruction: | English | ||||
| Course Condition: | |||||
| Does the Course Require Work Experience?: | No | ||||
| Type of course: | University Elective | ||||
| Course Level: |
|
||||
| Mode of Delivery: | E-Learning | ||||
| Course Coordinator: | Dr. Öğr. Üy. DENİZ SERTEL ŞELALE | ||||
| Course Lecturer(s): | İbrahim Çağatay Acuner, Pınar Yurdakul Mesutoğlu, Deniz Sertel Şelale, Ayhan Mehmetoğlu | ||||
| Course Assistants: |
| Course Objectives: | The aim of this course is to convey information on; - fundamentals of human microbiota & microbiome - formation and development of microbiota - factors that affect the composition of microbiota - effects of microbiota on human health - association of microbiota with diseases - pharmaceutical modulation of microbiota |
| Course Content: | This course includes theoretical lectures regarding human microbiota and it’s effects on human health and association with diseases. |
|
The students who have succeeded in this course;
1) Should be able to define microbiota, microbiome and metagenome concepts. 2) Should be able to describe human microbiota and explain how its formed. 3) Should be able to explain the factors that affect the composition of microbiota. 4) Should be able to define the effects of microbiota on human health. 5) Should be able to explain the association of microbiota with diseases. 6) Should be able to discuss the use of pharmaceutical preparations that modulate microbiota in promotion of health. |
| Week | Subject | Related Preparation |
| 1) | Introduction to microbiota, microbiome and metagenome concepts | Review of the course materials |
| 2) | Transmission and development of microbiota | Review of the course materials |
| 3) | Nutritional modulation of the gut microbiome | Review of the course materials |
| 4) | Microbiota perturbations: Dysbiosis and Disease | Review of the course materials |
| 5) | Microbiota & Obesity; Type-2 Diabetes and Cancer | Review of the course materials |
| 6) | Gut microbiome and host immunity | Review of the course materials |
| 7) | Microbiota & Gut-Brain / Gut-Lung Axis | Review of the course materials |
| 8) | Mid term exam | Review of the course materials |
| 9) | Consumption of antibiotics and microbiota | Review of the course materials |
| 10) | Fecal transplantation | Review of the course materials |
| 11) | Nutritional modulation of the gut microbiome for metabolic health and healthy longevity | Review of the course materials |
| 12) | Prebiotics, probiotics and next generation pharmaceutical modulation of the gut microbiome | Review of the course materials |
| 13) | One health approach, and microbiota | Review of the course materials |
| 14) | Multi omics approach and future trends | Review of the course materials |
| 15) | Final Exam | Review of the course materials |
| Course Notes / Textbooks: | Tungland B. Human Microbiota in Health and Disease. Academic Press;2018. ISBN 9780128146491 |
| References: | • Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012 Oct;13(10):701-12. doi: 10.1038/nrn3346. Epub 2012 Sep 12. PMID: 22968153. • Sonnenburg JL, Bäckhed F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016 Jul 7;535(7610):56-64. doi: 10.1038/nature18846. PMID: 27383980; PMCID: PMC5991619. • Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015 Apr-Jun;28(2):203-209. PMID: 25830558; PMCID: PMC4367209. • Kim S, Covington A, Pamer EG. The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens. Immunol Rev. 2017 Sep;279(1):90-105. doi: 10.1111/imr.12563. PMID: 28856737; PMCID: PMC6026851. • Sonnenburg JL, Sonnenburg ED. Vulnerability of the industrialized microbiota. Science. 2019 Oct 25;366(6464):eaaw9255. doi: 10.1126/science.aaw9255. PMID: 31649168. • Mikroorganizmalar ve insan vücudu ile olan etkileşimleri Microorganisms and their interaction with human body. Rıdvan Çetin et al. DOI: 10.5455/pmb.1-1422383762 • Tang ZZ, Chen G, Hong Q, Huang S, Smith HM, Shah RD, Scholz M, Ferguson JF. Multi-Omic Analysis of the Microbiome and Metabolome in Healthy Subjects Reveals Microbiome-Dependent Relationships Between Diet and Metabolites. Front Genet. 2019 May 17;10:454. doi: 10.3389/fgene.2019.00454. PMID: 31164901; PMCID: PMC6534069. • İntestinal mikrobiyota ve obezite ilişkisi, The relationship between intestinal microbiota and obesity. Tuba tekin et al. Derleme 2018; 27: 95-99. • Ichim TE, Patel AN, Shafer KA. Experimental support for the effects of a probiotic/digestive enzyme supplement on serum cholesterol concentrations and the intestinal microbiome. J Transl Med. 2016 Jun 22;14(1):184. doi: 10.1186/s12967-016-0945-2. PMID: 27333764; PMCID: PMC4918082. • Kuugbee ED, Shang X, Gamallat Y, Bamba D, Awadasseid A, Suliman MA, Zang S, Ma Y, Chiwala G, Xin Y, Shang D. Structural Change in Microbiota by a Probiotic Cocktail Enhances the Gut Barrier and Reduces Cancer via TLR2 Signaling in a Rat Model of Colon Cancer. Dig Dis Sci. 2016 Oct;61(10):2908-2920. doi: 10.1007/s10620-016-4238-7. Epub 2016 Jul 6. PMID: 27384052. • Salvucci E. The human-microbiome superorganism and its modulation to restore health. Int J Food Sci Nutr. 2019 Nov;70(7):781-795. doi: 10.1080/09637486.2019.1580682. Epub 2019 Mar 7. PMID: 30843443. |
| Course Learning Outcomes | 1 |
2 |
3 |
4 |
5 |
6 |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Program Outcomes | |||||||||||
| 1) Applies and develops the universal and social dimensional effects of basic, professional and technological knowledge in the field of pharmacy as well as pharmacy practice interdisciplinary by following legal, deontological and ethical rules. | |||||||||||
| 2) Defines the terminology related to the pharmacy profession; solves problems , accesses scientific information in the field of pharmacy, after monitoring and evaluating the current literature, applies , communicates, shares by using information technologies effectively and efficiently. | |||||||||||
| 3) Uses theoretical and practical knowledge about the anatomical structure of the human body, the physiological working principles of systems, biochemical, immunological events in the organism and microorganisms. | |||||||||||
| 4) Uses basic and advanced analytical techniques and methods by running qualitative/quantitative analyzes and interprets the findings by using appropriate statistical methods. | |||||||||||
| 5) Defines medicinal plants, herbal drugs and active substances; gains the skills for the development of natural products used for medical purposes. | |||||||||||
| 6) Applies patient-centered and individualized pharmaceutical care service together with other healthcare personnel within the framework of rational drug use by using the principles of clinical pharmacy, pharmacoeconomics, pharmacotherapy and phytotherapy. | |||||||||||
| 7) Knows the biological properties, structure-activity relationships, and metabolisms of drugs and gains the skill for the synthesize and development of new drug candidates. | |||||||||||
| 8) He/She is competent at formulations, production, stability, quality assurance, licensing, patent studies, legal regulations of products containing natural origin and / or synthetic active substances, advanced therapy medicinal products, radiopharmaceuticals and cosmetic products. | |||||||||||
| 9) Interprets the pharmacokinetic and pharmacodynamic properties of drugs, the factors that change their effect, their toxic effects, pharmacolygical activities and their risk assessment method. Reports the drug interactions and adverse drug reactions, monitors and applies the theoretical/practical knowledge for preventing them. | |||||||||||
| 10) As a health professional in his/her profession he/she acts as a caregiver, decision maker, communicator, manager, lifelong learner, instructor, leader and researcher, he/she complies with the principles of evidence-based pharmacy by making teamwork for the benefit of society, national and universal values. | |||||||||||
| 11) He/She works in various fields such as community pharmacy, hospitals, pharmaceutical medical devices, herbal products and cosmetics sectors, health institutions and agencies, clinical research organizations , universities and R&D centers. | |||||||||||
| No Effect | 1 Lowest | 2 Average | 3 Highest |
| Program Outcomes | Level of Contribution | |
| 1) | Applies and develops the universal and social dimensional effects of basic, professional and technological knowledge in the field of pharmacy as well as pharmacy practice interdisciplinary by following legal, deontological and ethical rules. | |
| 2) | Defines the terminology related to the pharmacy profession; solves problems , accesses scientific information in the field of pharmacy, after monitoring and evaluating the current literature, applies , communicates, shares by using information technologies effectively and efficiently. | |
| 3) | Uses theoretical and practical knowledge about the anatomical structure of the human body, the physiological working principles of systems, biochemical, immunological events in the organism and microorganisms. | |
| 4) | Uses basic and advanced analytical techniques and methods by running qualitative/quantitative analyzes and interprets the findings by using appropriate statistical methods. | |
| 5) | Defines medicinal plants, herbal drugs and active substances; gains the skills for the development of natural products used for medical purposes. | |
| 6) | Applies patient-centered and individualized pharmaceutical care service together with other healthcare personnel within the framework of rational drug use by using the principles of clinical pharmacy, pharmacoeconomics, pharmacotherapy and phytotherapy. | |
| 7) | Knows the biological properties, structure-activity relationships, and metabolisms of drugs and gains the skill for the synthesize and development of new drug candidates. | |
| 8) | He/She is competent at formulations, production, stability, quality assurance, licensing, patent studies, legal regulations of products containing natural origin and / or synthetic active substances, advanced therapy medicinal products, radiopharmaceuticals and cosmetic products. | |
| 9) | Interprets the pharmacokinetic and pharmacodynamic properties of drugs, the factors that change their effect, their toxic effects, pharmacolygical activities and their risk assessment method. Reports the drug interactions and adverse drug reactions, monitors and applies the theoretical/practical knowledge for preventing them. | |
| 10) | As a health professional in his/her profession he/she acts as a caregiver, decision maker, communicator, manager, lifelong learner, instructor, leader and researcher, he/she complies with the principles of evidence-based pharmacy by making teamwork for the benefit of society, national and universal values. | |
| 11) | He/She works in various fields such as community pharmacy, hospitals, pharmaceutical medical devices, herbal products and cosmetics sectors, health institutions and agencies, clinical research organizations , universities and R&D centers. |
| Semester Requirements | Number of Activities | Level of Contribution |
| Homework Assignments | 1 | % 20 |
| Midterms | 1 | % 20 |
| Final | 1 | % 60 |
| total | % 100 | |
| PERCENTAGE OF SEMESTER WORK | % 40 | |
| PERCENTAGE OF FINAL WORK | % 60 | |
| total | % 100 | |
| Activities | Number of Activities | Preparation for the Activity | Spent for the Activity Itself | Completing the Activity Requirements | Workload | ||
| Course Hours | 14 | 0 | 3 | 42 | |||
| Homework Assignments | 1 | 20 | 1 | 21 | |||
| Midterms | 1 | 30 | 1 | 31 | |||
| Final | 1 | 30 | 1 | 31 | |||
| Total Workload | 125 | ||||||